Fierce Pharma

NOVEMBER 23, 2022

price tag, CSL and uniQure's hemophilia B gene therapy crosses FDA finish line. Sporting a $3.5M Wed, 11/23/2022 - 10:10.

Gene Therapy 120

Gene Therapy Gene 120

Pharmaceutical Technology

NOVEMBER 9, 2022

Despite their potential multi-million-dollar sticker price, if haemophilia treatments by BioMarin and CSL Behring prove durable, they could help patients save money compared to current treatments, experts note. A fair price for CSL Behring’s haemophilia B treatment etranacogene dezaparvovec would be between $2.93–2.96 million ($1.8

Gene Therapy 278

Gene Therapy Gene FDA Approval Medicine 278

Drug Discovery World

DECEMBER 20, 2022

The CHMP has recommended conditional marketing authorisation of CSL’s (etranacogene dezaparvovec), a one-time gene therapy for the treatment of appropriate adults with the disease. . Concerns about the high price tag have been raised in an article in Nature, particularly whether it will be affordable for low to middle-income countries. .

Gene Therapy 52

Gene Therapy Gene Clinical Trials Clinical Trials 52

Pharmaceutical Technology

FEBRUARY 10, 2023

On November 22, 2022, the FDA approved CSL Behring’s Hemgenix (etranacogene dezaparvovec), the first gene therapy treatment for hemophilia B, with a staggering manufacturer price of $3.5 This is not the first treatment to come with a high price tag.

Gene Therapy 263

Gene Therapy Marketing Gene Drugs 263

Pharmaceutical Technology

MAY 15, 2023

Innovation S-curve for the pharmaceutical industry Peptide nano-particle conjugates is a key innovation area in the pharmaceutical industry By tagging peptides with nanoparticles, peptide nano-particle conjugates allow enhanced control over their biological behaviour, overcoming intrinsic limitations of the individual materials.

Antibody 130

Antibody DNA Development Vaccination 130

Pharmaceutical Technology

JUNE 21, 2023

CSL announced the first patient with haemophilia B has been treated with its recently approved gene therapy Hemgenix (etranacogene dezaparvovec). The high price tag may be hard to defend , but with lifetime treatment costs for haemophilia B reaching as high as $23m for some, the single-dose treatment could prove far more cost-effective.

Gene Therapy 246

Gene Therapy Gene Protein Sales 246

XTalks

NOVEMBER 24, 2022

million, CSL Behring’s single-dose therapy has become the most expensive drug in the world. The Hemgenix approval was granted to CSL Behring , a rare disease biotech company based in Pennsylvania, which developed Hemgenix jointly with gene therapy biotech uniQure. With a list price of $3.5

Gene Therapy 52

Gene Therapy Gene FDA Approval Genetics 52